{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:19:48Z","timestamp":1787933988977,"version":"build-2784847793"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2018-12367572"],"award-info":[{"award-number":["GR-2018-12367572"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ijid.2021.10.028","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:13:58Z","timestamp":1634328838000},"page":"213-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-8635","authenticated-orcid":false,"given":"Paolo","family":"Gaibani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-5973","authenticated-orcid":false,"given":"Matteo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Crovara Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Lazzarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0730-742X","authenticated-orcid":false,"given":"Donatella","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Amadesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ambretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijid.2021.10.028_bib0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/antibiotics9100676","article-title":"Some Suggestions from PK\/PD Principles to Contain Resistance in the Clinical Setting-Focus on ICU Patients and Gram-Negative Strains","volume":"9","author":"Adembri","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.ijid.2021.10.028_bib0002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented Renal Clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.ijid.2021.10.028_bib0003","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14787210.2017.1338139","article-title":"Optimizing \u03b2-lactams treatment incritically-ill patients using pharmacokinetics\/pharmacodynamics targets: are first conventional doses effective?","volume":"15","author":"Delattre","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.ijid.2021.10.028_bib0004","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jac\/dky082","article-title":"In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment","volume":"73","author":"Gaibani","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ijid.2021.10.028_bib0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40265-018-0891-9","article-title":"Individualising Therapy to Minimize Bacterial Multidrug Resistance","volume":"78","author":"Heffernan","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2021.10.028_bib0006","article-title":"Minireview on Novel Anti-infectious Treatment Options and Optimized Drug Regimens for Sepsis","volume":"8","author":"Hites","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.ijid.2021.10.028_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.12585","article-title":"Ceftazidime\/avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups","volume":"12","author":"Li","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.ijid.2021.10.028_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40261-015-0283-9","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies","volume":"35","author":"Merdjan","year":"2015","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.ijid.2021.10.028_bib0009","doi-asserted-by":"crossref","first-page":"e02497","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for Ceftazidime\/avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ijid.2021.10.028_bib0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ijid.2021.10.028_bib0011","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/jac\/dkx001","article-title":"Determining \u03b2-lactam exposure threshold to suppress resistance development in Gram-negative bacteria","volume":"72","author":"Tam","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijid.2021.10.028_bib0012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/beta-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122100816X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122100816X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:06:53Z","timestamp":1761120413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197122100816X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":12,"alternative-id":["S120197122100816X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.10.028","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}